Safety of 5-hydroxy-L-tryptophan

Toxicology Letters

Volumn 150, Issue 1, 2004, Pages 111-122

  Das, Yesu T ^a   Bagchi, Manashi ^b   Bagchi, Debasis ^b   Preuss, Harry G ^c  

^a ISSI Laboratories Inc   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5 HT; 5 HTP; 5 Hydroxy L tryptophan; 5 L HTP; 5 OH Trp; Dietary supplement; EMS; EMS related disorder; Eosinophilia myalgia syndrome; Eosinophilia myalgia syndrome related disorder; L Trp; L Trp 4,5D; L Tryptophan; LT; Peak X; Tryptophan 4,5 dione

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMINO ACID; CARBIDOPA; FLUOXETINE; LEVODOPA; PARACETAMOL; PAROXETINE; PREDNISONE; SEROTONIN; SERTRALINE; TETRAHYDROBIOPTERIN; TRYPTOPHAN;

AGITATION; ARTIFACT; BIOSYNTHESIS; CHEMICAL ANALYSIS; CHROMATOGRAPHY; CLINICAL FEATURE; CONFUSION; CONSUMER; CONTAMINATION; DELIRIUM; DIAPHORESIS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME DEFICIENCY; EOSINOPHILIA MYALGIA SYNDROME; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; INDUSTRY; LABORATORY TEST; MARKET; MEDICAL DOCUMENTATION; METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SAFETY; SAMPLE; SEROTONIN SYNDROME; TACHYCARDIA; TOXIC OIL SYNDROME;

EID: 1842531695     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.12.070     Document Type: Article

References (91)

1. Adachi J., Mio T., Ueno Y., Naito T., Nishimura A., Fujiwara S., Sumino K., Tatsuno Y. Identification of four metabolites of 3-(phenylamino)alanine, a constituent of L-tryptophan products implicated in eosinophilia syndrome in rats. Arch. Toxicol. 68:1994;500-505.
2. Adachi J., Gomez M., Smith C.C., Sternberg E.M. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia. Arch. Toxicol. 69:1995;266-270.
3. 11C ]-5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers Acta Psychiatr. Scand. 83:1991;449-455.
4. Angst J., Woggon B., Schoept J. The treatment of depression with L-5-tryptophan versus imipramine: results of two open and one double-blind study. Arch. Psychiatr. Nervenkr. 224:1977;175-186.
5. Arnow L.E. The preparation of dopa-melanin. Science. 87:1938;308.
6. Aviram M., Cogan U., Mokady S. Excessive dietary tryptophan enhances plasma lipid peroxidation in rats. Atherosclerosis. 88:1991;29-34.
7. Barlet P., Pailard P. Etude clinique du 5-hydroxytryptophan dans les etats depressifs du troisieme age. Cah. Med. Lyon. 50:1973;1985-1991.
8. Boiardi A., Crenna P., Merati B., Negri S., Tansini E., Bussone G. 5-OH-Tryptophan in migraine: clinical and neurophysiological considerations. J. Neurol. 225:1981;41-46.
9. Bono G., Criscuoli M., Martignoni E., Salmon S., Nappi G. Serotonin precursors in migraine prophylaxis. Adv. Neurol. 33:1982;357-363.
10. Bono G., Micieli G., Sances G., Calvani M., Nappi G. L-HTP treatment in primary headaches: an attempt in clinical identification of responsive patients. Cephalalgia. 4:1984;159-165.
11. Brodie, H.K.H., Sack, R., Siever, L., 1973. Clinical studies of L-5-hydroxytryptophan in depression. In: Barchas, J., Usdin, E. (Eds.), Serotonin and Behavior. Academic Press, New York, pp. 549-559.
12. Byerley W.F., Judd L.L., Reimherr F.W., Grosser B.I. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J. Clin. Psychopharmacol. 7:1987;127-137.
13. Cangiano C., Ceci F., Cascino A., Del Ben M., Laviano A., Muscritoli M., Antonucci F., Rossi-Fanelli F. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am. J. Clin. Nutr. 56:1992;863-867.
14. Caruso I., Puttini P.S., Cazzola M., Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J. Int. Med. Res. 18:1990;201-209.
15. Centers for Disease Control, 1989a. Eosinophilia-myalgia syndrome: New Mexico. Morb. Mortal. Wkly. Rep. 38, 765-767.
16. Centers for Disease Control, 1989b. Eosinophilia-myalgia syndrome: New Mexico, Minnesota, Oregon and New York. Morb. Mortal. Wkly. Rep. 38, 785-788.
17. Chartash E.K., Given W.P., Vishnubhakat S.M., Susin M., Coffey E.L. Jr., Farmer P.M., Albanese J.M., Kaplan M.H., Furie R.A. L-Tryptophan induced eosinophilia-myalgia syndrome. J. Rheumatol. 17:1990;1527-1533.
18. Clauw D.J. Animal models of the eosinophilia-myalgia syndrome. J. Rheumatol. 23(Suppl. 46):1996;93-98.
19. Conte G. Lithium, imipramine and hydroxytryptophan in resistant depression. Br. J. Psychiatry. 152:1988;720.
20. Criswell L.A., Sack K.E. Tryptophan-induced eosinophilia-myalgia syndrome. West. J. Med. 153:1990;269-274.
21. Crofford L.J., Rader J.I., Dalakas M.C., Hill R.H. Jr., Page S.W., Needham L.L., Brady L.S., Heyes M.P., Wilder R.L., Gold P.W., Isabel L., Smith C. L-Tryptophan implicated in human eosinophilia-myalgia syndrome causes fascitis and perimyositis in the Lewis rat. J. Clin. Invest. 86:1990;1757-1763.
22. De Benedittis G., Massei R. Serotonin precursors in chronic primary headache. A double-blind cross-over study L-5-hydroxytryptophan versus placebo. J. Neurosurg. Sci. 29:1985;239-248.
23. De Giorgis G., Miletto R., Iannuccelli M., Camuffo M., Scerni S. Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study - L-5-HTP versus placebo. Drugs Exp. Clin. Res. 13:1987;425-433.
24. Den Boer J.A., Westenberg H.G. Behavioral, neuroendocrine and biochemical effects of 5-hydroxytrptophan administration in panic disorder. Psychiatry Res. 31:1990;267-278.
25. De Schryver-Kecskemeti K., Gramlich T.L., Crofford L.J., Rader J.I., Page S.W., Needham L.L., Hill R.H. Jr., Sternburg E.M. Environmental pathology. Mast cell and eosinophil infiltration in intestinal mucosa of Lewis rats treated with L-tryptophan implicated in human eosinophilia-myalgia syndrome. Mod. Pathol. 4:1991;354-357.
26. Dryhurst, G., 1998. Putative endogenous neurotoxins derived from the biogenic amine neurotransmitters. In: Moser, A. (Ed.), Pharmacology of Endogenous Neurotoxins. Birkhäuser, Basel, pp. 63-128.
27. Dwuma-Badu D., Watson W.H., Gopalakrishna E.M., Okarter T.U., Knapp J.E., Schiff P.L. Jr., Slatkin D.J. Constituents of West African medicinal plants. XVI. Griffonin and griffonilide, novel constituents of Griffonia simplicifolia. Lloydia. 39:1976;385-390.
28. Emslie-Smith A.M., Mayeno A.N., Nakano S., Gleich G.J., Engel A.G. 1,1′-Ethylidenebis[tryptophan] includes pathologic alterations in muscle similar to those observed in the eosinophilic-myagia syndrome. Neurology. 44:1994;2390-2392.
29. Farinelli S., Mariani A., Grimaldi A., Mariani M., Iannessi A., De Rosa F. Eosinophilia-myalgia syndrome associated with 5-OH-tryptophan. Description of a case. Recent Prog. Med. 82:1991;381-384.
30. FDA/CDER, 1998. ANDAs: Impurities in Drug Substances. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, Maryland.
31. Fujiwara J., Otsuki S. Subtype of affective psychoses classified by response on amine precursors and monoamine metabolism. J. Oral Pathol. 2:1973;93-100.
32. Glickstein S.L., Gertner E., Smith S.A., Roelofs R.I., Hathaway D.E., Schlesinger P.A., Schned E.S. Eosinophilia-myalgia syndrome associated with tryptophan use. J. Rheumatol. 17:1990;1534-1543.
33. Guilleminault C.M., Cathala J.P., Castaigne P. Effects of 5-hydroxytryptophan on sleep of a patient with brain-stem lesion. Electroencephalogr. Clin. Neurophysiol. 34:1973;177-184.
34. Hertzman P.A., Blevins W.L., Mayer J., Mayer J., Greenfield B., Ting M., Gleich G.J. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N. Eng. J. Med. 322:1990;869-873.
35. Humphries K., Dryhurst G. Electrochemical oxidation of 5-hydroxytryptophan in acid solution. J. Pharm. Sci. 76:1987;839-847.
36. Johnson K.L., Klarskov K., Benson L.M., Williamson B.L., Gleich G.J., Naylor S. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan. J. Rheumatol. 26:1999;2714-2717. (Letter).
37. Joly P., Lampert A., Thomine E., Lauret P. Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and cardidopa. J. Am. Acad. Dermatol. 25:1991;332-333.
38. Kahn R.S., Westenberg H.G.M. L-5-Hydroxytryptophan in the treatment of anxiety disorders. J. Affect. Disord. 8:1985;197-200.
39. Kaneko M., Kumashiro H., Takahashi Y. L-5-HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patients. Neuropsychobiology. 5:1979;232-240.
40. Kaufman L.D., Seidman R.J., Gruber B.L. L-Tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis: a clinicopathologic and laboratory study of 25 patients. Medicine (Baltimore). 69:1990;187-199.
41. Kilbourne E.M. Eosinophilia-myalgia syndrome: coming to grips with a new illness. Epidemiol. Rev. 14:1992;16-36.
42. Kilbourne E.M., Philen R.M., Kamb M.L., Falk H. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. J. Rheumatol. 23(Suppl. 46):1996;81-91.
43. Kilbourne E.M., Rigau-Perez J.G., Heath C.W. Jr., Zack M.M., Falk H., Martin-Marcos M., de Carlos A. Clinical epidemiology of toxic-oil syndrome. Manifestations of a new illness. N. Eng. J. Med. 309:1983;1408-1414.
44. Klarskov K., Johnson K.L., Benson L.M., Gleich G.J., Naylor S. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Adv. Exp. Med. Biol. 467:1999;461-468.
45. Klarskov K., Johnson K.L., Benson L.M., Cragun J.D., Gleich G.J., Wrona M., Jiang X.-R., Dryhurst G., Naylor S. Structural characterization of a case-implicated contaminant, "peak X", in commercial preparations of 5-hydroxytryptophan. J. Rheumatol. 30:2003;89-95.
46. Longo G., Rudio I., Iannuccelli M., Strinati R., Panizon F. Treatment of essential headache in developmental age with L-5-HTP (cross over double-blind study versus placebo). Pediatr. Med. Chir. 6:1984;241-245.
47. Lopez-Ibor Alino J.J., Ayuso Guiterrez J.L., Montejo Iglesias M.L. 5-Hydroxytryptophan (5-HTP) and an MAOI (nialamide) in the treat of depressions. Int. Pharmacopsychiatry. 11:1976;8-15.
48. Love L.A., Rader J.I., Crofford L.J., Roybourne R.B., Principato M.A., Page S.W., Trucksess M.W., Smith M.J., Dugan E.M., Turner M.L., Zelazowski E., Zelazowski P., Sternberg E.M. Pathological and immunological effects of ingesting L-tryptophan and 1,1′-ethylidenebis(L-tryptophan) in Lewis rats. J. Clin. Invest. 91:1993;804-811.
49. Magnussen I.E., Nielsen-Kudsk F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in a steady state. Acta Pharmacol. Toxicol. 46:1980;257-262.
50. Maissen C.P., Ludin H.P. Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine. Schweiz. Med. Wochenschr. 121:1991;1585-1590.
51. Martin R.W., Duffy J., Engel A.G., Lie J.T., Bowles C.A., Moyer T.P., Gleich G.J. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion: clinical features in 20 patients and aspects of pathophysiology. Ann. Intern. Med. 113:1990;124-134.
52. Mason H.S. The chemistry of melanin. III. Mechanism of the oxidation of dihydroxyphenylalnine by tyrosinase. J. Biol. Chem. 172:1948;83-99.
53. Matussek N., Angst J., Benkert O., Gmur M., Papousek M., Ruther E., Waggon B. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients. Adv. Biochem. Psychopharmacol. 11:1974;399-404.
54. Mayeno A.N., Gleich G.J. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale. Trends Biotechnol. 12:1994;346-352.
55. Mendlewicz J., Youdim M.B.H. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J. Affect. Disord. 2:1980;137-146.
56. Michelson D., Page S.W., Casey R., Trucksess M.W., Love L.A., Milstien S., Wilson C., Massaquoi S.G., Crofford L.J., Hallett M., Gold P.W., Sternberg E.M. An eosinophilia-myaligia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J. Rheumatol. 21:1994;1261-1265.
57. Milburn D.S., Myers C.W. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome. DICP. 25:1991;1259-1262.
58. Nakajima T., Kudo Y., Kaneko Z. Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug. Folia Psychiatr. Neurol. Jpn. 32:1978;223-230.
59. Nicolodi M., Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism: serotonin as the common clue for pathogenesis and therapy. Adv. Exp. Med. Biol. 398:1996;373-379.
60. Ogawa Y., Adachi J., Tatsuno Y. Accumulation of 1-methyl-tetrahydro-beta- carboline-3-carboxylic acid in blood and organs of rat. Possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Arch. Toxicol. 67:1993;290-293.
61. Pawalek J.M., Körner A.M. The biosynthesis of mammalian melanin. Am. Scientist. 70:1982;136-145.
62. Persson T., Roos B.E. 5-Hydroxytryptophan for depression. Lancet. 2:1967;987-988.
63. Philen R.M., Eidson M., Kilbourne E.M., Sewell C.M., Voorhees R. Eosinophilia-myalgia syndrome: a clinical case series of 21 patients. New Mexico Eosinophilia-Myalgia Syndrome Study Group. Arch. Intern. Med. 151:1991;533-537.
64. Philen R.M., Hill R.H. Jr., Fanders W.D., Caudill S.P., Needham L., Sewell L., Sampson E.J., Falk H., Kilbourne E.M. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The eosinophilia-myalgia studies of Oregon, New York and New Mexico. Am. J. Epidemiol. 138:1993;154-159.
65. Plieninger H., Suhr K. Die Synthese des [1-Acetylindolyl-(4)]- acetaldehyds, des 4-Cyanmethyl-indols und der Indolyl-(4)-essigsäure aus α-Naphthylamin. Chem. Ber. 89:1956;270-278.
66. Poldinger W., Calanchini B., Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytrptophan and fluvoxamine. Psychopathology. 24:1991;53-81.
67. Posada de la Paz M., Philen R.M., Borda A.I. Toxic oil syndrome. The perspective after 20 years. Epidemiol. Rev. 23:2001;231-247.
68. Puttini P.S., Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J. Intern. Med. Res. 20:1992;182-189.
69. Raper H.S. The aerobic oxidases. Physiol. Rev. 8:1928;245-282.
70. Sano I. "Precursor therapy" with active amines. 1. Treatment of depression by L-5-HTP (L-5-hydroxytryptophan). Psychiatr. Neurol. Jpn. 73:1971a;809-815.
71. Sano I. "Precursor therapy" with active amines. 2. Treatment of Parkinson's disease by L-5-HTP (L-5-hydroxytryptophan). Psychiatr. Neurol. Jpn. 73:1971b;835-839.
72. Sano I. L-5-Hydroxytryptophan (L-5-HTP) therapy. Folia Psychiatr. Neurol. Jpn. 26:1972;7-17.
73. Sato F., Hagiwara Y., Kawase Y. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome. Arch. Toxicol. 69:1995;444-449.
74. Silver R.M., Heyes M.P., Maize J.C., Quearry B., Vionnet-Fuasset M., Sternberg E.M. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N. Engl. J. Med. 322:1990;874-881.
75. Silver R.M., Ludwicka A., Hampton M., Ohba T., Bingel S.A., Smith T., Harley R.A., Maize J., Heyes M.P. A murine model of the eosinophilia-myalgia syndrome induced by 1,1′-ethylidenebis(L-tryptophan). J. Clin. Invest. 93:1994;1473-1480.
76. Simic M.G., al-Sheikhyly M., Jovanovic S.V. Inhibition of free radical processes by antioxidants - tryptophan and 5-hydroxytryptophan. Bibl. Nutr. Dieta. 43:1989;288-296.
77. Soulairac A., Lambinet H. Effect of 5-hydroxytryptophan, a serotonin precursor, on sleep disorders. Ann. Med. Psychol. 1:1977;792-798.
78. Stieber T. Three New Mexico women contract unusual medical syndrome. Albuquerque J. 7:1989;1.
79. Takahashi S., Kondo H., Kato N. Effect of L-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients. J. Psychiatr. Res. 12:1975;177-187.
80. Teuber H.-J., Staiger G. Reaktionen mit Nitrosodisulfonat. VI. Mitteil.: Oxyindole und Indolchinone aus Dihydroindolen. Chem. Ber. 87:1954;1251-1255.
81. Titus F., Davalos A., Alom J., Codina A. 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial. Eur. Neurol. 25:1986;327-329.
82. van Hiele L.J. L-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with 'therapy-resistant' depressions. Neuropsychobiology. 6:1980;230-240.
83. van Praag H.M., Korf J., Dols L.C., Schut T. A pilot study of the predictive value of the probenecid test in the application of 5-Hydroxytryptophan as antidepressant. Psychopharmacologia. 25:1972;14-21.
84. van Praag H.M., van den Burg W., Bos E.R., Dols L.C. 5-Hydroxytryptophan in combination with clomipramine in "therapy-resistant" depression. Psychopharmacologia. 38:1974;267-269.
85. Varga J., Heiman-Patterson T.D., Emery D.L., Griffin B., Lally E.V., Uitto J.J., Jimenez S.A. Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Semin. Arthritis Rheum. 19:1990;313-328.
86. Westenberg H.G.M., den Boer J.A. Serotonin function in panic disorder: effect of L-5-hydroxytryptophan in patients and controls. Psychopharmacology. 98:1989;283-285.
87. Williamson B.L., Klarskov K., Tomlinson A.J., Gleich G.J., Naylor S. Problems with over-the-counter 5-hydroxy-L-tryptophan. Nat. Med. 4:1998;983. (Letter).
88. Wu Z., Dryhurst G. 7-S-Glutathionyl-tryptophan-4,5-dione: formation from 5-hydroxytryptophan and reaction with glutathione. Bioorg. Chem. 24:1996;127-149.
89. Wyatt R.J., Zarcone V., Engelman K., Dement W.C., Snyder F., Sjoerdsma A. Effects of 5-hydroxytryptophan on the sleep of normal human subjects. Electroencephalogr. Clin. Neurophysiol. 30:1971;505-509.
90. Yamaguchi Y., Tsunoda J., Suda T., Miura Y., Shioiri-Nakano K., Kasahara T. Effect of synthesized constituents in the L-tryptophan product on the differentiation of eosinophils and the induction of IL-6: a possible cause of eosinophilia-myalgia syndrome. Biochem. Biophys. Res. Commun. 178:1991;1008-1013.
91. Zmilacher K., Battegay R., Gastpar M. L-5-Hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology. 20:1988;28-35.